These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer. Welti J; Rodrigues DN; Sharp A; Sun S; Lorente D; Riisnaes R; Figueiredo I; Zafeiriou Z; Rescigno P; de Bono JS; Plymate SR Eur Urol; 2016 Oct; 70(4):599-608. PubMed ID: 27117751 [TBL] [Abstract][Full Text] [Related]
3. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer. Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736 [TBL] [Abstract][Full Text] [Related]
4. Discovery of Potent 17β-Hydroxywithanolides for Castration-Resistant Prostate Cancer by High-Throughput Screening of a Natural Products Library for Androgen-Induced Gene Expression Inhibitors. Xu YM; Liu MX; Grunow N; Wijeratne EM; Paine-Murrieta G; Felder S; Kris RM; Gunatilaka AA J Med Chem; 2015 Sep; 58(17):6984-93. PubMed ID: 26305181 [TBL] [Abstract][Full Text] [Related]
5. High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer. Jansson KH; Tucker JB; Stahl LE; Simmons JK; Fuller C; Beshiri ML; Agarwal S; Fang L; Hynes PG; Alilin AN; Lake R; Abbey YC; Cawley J; Tice CM; Yin J; McKnight C; Klummp-Thomas C; Zhang X; Guha R; Hoover S; Simpson RM; Nguyen HM; Corey E; Thomas CJ; Proia DA; Kelly K Sci Rep; 2018 Nov; 8(1):17239. PubMed ID: 30467317 [TBL] [Abstract][Full Text] [Related]
6. Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. Lawrence MG; Obinata D; Sandhu S; Selth LA; Wong SQ; Porter LH; Lister N; Pook D; Pezaro CJ; Goode DL; Rebello RJ; Clark AK; Papargiris M; Van Gramberg J; Hanson AR; Banks P; Wang H; Niranjan B; Keerthikumar S; Hedwards S; Huglo A; Yang R; Henzler C; Li Y; Lopez-Campos F; Castro E; Toivanen R; Azad A; Bolton D; Goad J; Grummet J; Harewood L; Kourambas J; Lawrentschuk N; Moon D; Murphy DG; Sengupta S; Snow R; Thorne H; Mitchell C; Pedersen J; Clouston D; Norden S; Ryan A; Dehm SM; Tilley WD; Pearson RB; Hannan RD; Frydenberg M; Furic L; Taylor RA; Risbridger GP Eur Urol; 2018 Nov; 74(5):562-572. PubMed ID: 30049486 [TBL] [Abstract][Full Text] [Related]
7. Dual androgen receptor (AR) and STAT3 inhibition by a compound targeting the AR amino-terminal domain. Hua Y; Azeem W; Shen Y; Zhang S; Olsen JR; Øyan AM; Ke X; Zhang W; Kalland KH Pharmacol Res Perspect; 2018 Dec; 6(6):e00437. PubMed ID: 30410767 [TBL] [Abstract][Full Text] [Related]
8. Role of protein S in castration-resistant prostate cancer-like cells. Ning P; Zhong JG; Jiang F; Zhang Y; Zhao J; Tian F; Li W Endocr Relat Cancer; 2016 Aug; 23(8):595-607. PubMed ID: 27342144 [TBL] [Abstract][Full Text] [Related]
9. Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response. Ylitalo EB; Thysell E; Jernberg E; Lundholm M; Crnalic S; Egevad L; Stattin P; Widmark A; Bergh A; Wikström P Eur Urol; 2017 May; 71(5):776-787. PubMed ID: 27497761 [TBL] [Abstract][Full Text] [Related]
10. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N; Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502 [TBL] [Abstract][Full Text] [Related]
11. Identification of Core Genes and Potential Drugs for Castration-Resistant Prostate Cancer Based on Bioinformatics Analysis. Liang X; Hu K; Li D; Wang Y; Liu M; Wang X; Zhu W; Wang X; Yang Z; Lu J DNA Cell Biol; 2020 May; 39(5):836-847. PubMed ID: 32101033 [TBL] [Abstract][Full Text] [Related]
12. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor. Patki M; Huang Y; Ratnam M Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer. Chen X; Liu J; Cheng L; Li C; Zhang Z; Bai Y; Wang R; Han T; Huang C; Kong Y; Feng F; Liu X Prostate; 2020 Feb; 80(3):256-266. PubMed ID: 31856338 [TBL] [Abstract][Full Text] [Related]
14. B7-H3 as a Therapeutic Target in Advanced Prostate Cancer. Guo C; Figueiredo I; Gurel B; Neeb A; Seed G; Crespo M; Carreira S; Rekowski J; Buroni L; Welti J; Bogdan D; Gallagher L; Sharp A; Fenor de la Maza MD; Rescigno P; Westaby D; Chandran K; Riisnaes R; Ferreira A; Miranda S; Calì B; Alimonti A; Bressan S; Nguyen AHT; Shen MM; Hawley JE; Obradovic A; Drake CG; Bertan C; Baker C; Tunariu N; Yuan W; de Bono JS Eur Urol; 2023 Mar; 83(3):224-238. PubMed ID: 36114082 [TBL] [Abstract][Full Text] [Related]
15. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Shafi AA; Yen AE; Weigel NL Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952 [TBL] [Abstract][Full Text] [Related]
16. Potential Role for YB-1 in Castration-Resistant Prostate Cancer and Resistance to Enzalutamide Through the Androgen Receptor V7. Shiota M; Fujimoto N; Imada K; Yokomizo A; Itsumi M; Takeuchi A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26857528 [TBL] [Abstract][Full Text] [Related]
17. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9 Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814 [TBL] [Abstract][Full Text] [Related]
18. Longitudinal tracking of subpopulation dynamics and molecular changes during LNCaP cell castration and identification of inhibitors that could target the PSA-/lo castration-resistant cells. Rycaj K; Cho EJ; Liu X; Chao HP; Liu B; Li Q; Devkota AK; Zhang D; Chen X; Moore J; Dalby KN; Tang DG Oncotarget; 2016 Mar; 7(12):14220-40. PubMed ID: 26871947 [TBL] [Abstract][Full Text] [Related]
19. Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer. Yu J; Zhang L; Yan G; Zhou P; Cao C; Zhou F; Li X; Chen Y Eur J Med Chem; 2019 Jun; 171():265-281. PubMed ID: 30925341 [TBL] [Abstract][Full Text] [Related]
20. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Kettunen K; Boström PJ; Lamminen T; Heinosalo T; West G; Saarinen I; Kaipio K; Rantala J; Albanese C; Poutanen M; Taimen P Eur Urol; 2019 Oct; 76(4):430-434. PubMed ID: 31256944 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]